✦ LIBER ✦

PCN114 COST-EFFECTIVENESS ANALYSIS OF PEMETREXED/CISPLATIN IN THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY: RESULTS FOR THE ADENOCARCINOMA HISTOLOGY SUB-POPULATION

✍ Scribed by L Guidi; S Malik; D Valle; Y Asukai; K Taipale

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness analysis of pemetrexe

✍ Yumi Asukai; Amparo Valladares; Carlos Camps; Eifiona Wood; Kaisa Taipale; Jorge 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 781 KB

PCN43 COST COMPARISON OF ERLOTINIB VERSU

✍ S Ravera; S Walzer; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

PCN21 FIRST-LINE BEVACIZUMAB-BASED THERA

✍ K Berenson; C Chouaid; A Vergnenegre; S Sherman; S Walzer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

PCN6: MODELLING THE COST-EFFECTIVENESS O

✍ P Sharplin; UK Bose; J Holmes 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

PCN77 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ TE Ciuleanu; M Dediu; LN Minea; S Baculea; M Szkultecka-Debek 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

PCN87 A COST-EFFECTIVENESS ANALYSIS OF B

✍ HG Bischoff; D Heigener; C Wiesner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB